About Falma Laboratories Private Limited
Data last updated: 07 March 2026
Falma Laboratories Private Limited is a private limited company based in Bangalore, Karnataka, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 05 December 1985, the company has been in operation for over 41 years.
Registered with ROC Bangalore under CIN U24230KA1985PTC007328.
Capital: an authorised share capital of ₹3 Cr and a paid-up capital of ₹30 Lakh. It is led by directors including Kollenmareth Oomman Isaac and Prabir Kumar Sarkar.
Last AGM: 27 September 2025. Financial statements filed for year ended 31 March 2025. Office: No. 37/A2 Pillagumpe Industrial Area Hoskote, Bangalore, Karnataka, India – 562114.
As per the financials filed for FY 2022, the company reported a revenue of ₹21,651, a decline of 17.15% compared to the previous year.
The company is associated with 1 brand - Falma Laboratories. As per MCA filings, the company has satisfied charges of ₹1.3 Cr on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website falmalab.com.
-
Email*****@*****.com
-
Telephone**************
-
Website
-
Social Media**************
-
Registered AddressNo. 37/A2 Pillagumpe Industrial Area Hoskote, Bangalore, Karnataka, India – 562114
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Falma Laboratories Private Limited
Falma Laboratories Private Limited has one previous CIN (Corporate Identification Number): U24232KA1985PTC007328. The current CIN is U24230KA1985PTC007328, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230KA1985PTC007328 | Current |
| U24232KA1985PTC007328 | Previous |
Associated Brands with Falma Laboratories Private Limited
Falma Laboratories Private Limited operates one associated brand: Falma Laboratories. These brands represent Falma Laboratories Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures and exports high-quality pharmaceutical formulations for global markets. | falmalab.com |
Competitors & Alternatives of Falma Laboratories Private Limited
Brands and companies operating in the same space as Falma Laboratories Private Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jubilant Life Sciences
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Windlas
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
Unither
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
Recipharm
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
CoreRx
|
CDMO with a focus on early phase drug product development | Clearwater, United States, United States | 2006 |
MedPharm
|
Topical and inhaled drug delivery formulations are developed and manufactured. | Guildford, United Kingdom, United Kingdom | 1998 |
Auditor Details of Falma Laboratories Private Limited
Falma Laboratories Private Limited is audited by P N GANGULI & CO for the financial year 2020. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| P N GANGULI & CO | blur-value | blur-value | blur-value |
Board of Directors of Falma Laboratories Private Limited
Falma Laboratories Private Limited is currently managed by 4 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Kollenmareth Oomman Isaac
Also directs:
Abl Bio-Technologies Limited
|
Director | 21 Jun 2012 | 14 Years 0 Months | Current |
| Prabir Kumar Sarkar | Additional Director | 05 Aug 2013 | 12 Years 11 Months | Current |
|
Subhas Banerjee
Also directs:
Prudential Investment Ltd., Prudential Stock Broking Services Ltd, Eduexel Infotainment Limited and 5 more
|
Additional Director | 01 Jul 2015 | 11 Years 0 Months | Current |
|
Subrata Dasgupta
Also directs:
Prudential Investment Ltd., Prudential Stock Broking Services Ltd, Prudential Stock & Securities Ltd. and 5 more
|
Additional Director | 15 May 2019 | 7 Years 1 Months | Current |
Financials of Falma Laboratories Private Limited FY 2025 filings available
Falma Laboratories Private Limited reported revenue of ₹- (down -17.15% YoY) for FY 2022. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Falma Laboratories Private Limited
As of FY 2020, Falma Laboratories Private Limited's shareholding pattern shows 67.79% by promoters, 32.20% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Falma Laboratories Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Mar 1995 | Karnataka State Financial Corporation | ₹46.8 Lakh | Satisfied |
| 30 Apr 1994 | Karnataka State Finance Corporation | ₹23 Lakh | Satisfied |
| 14 May 1988 | Karnataka State Financial Corporation | ₹11.5 Lakh | Satisfied |
| 10 Aug 1987 | Karnataka State Financial Corporation | ₹48.5 Lakh | Satisfied |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Falma Laboratories Private Limited
Falma Laboratories Private Limited has a workforce of 0 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Falma Laboratories Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Falma Laboratories Private Limited
GSTIN & GST Filing Data of Falma Laboratories Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Falma Laboratories Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Falma Laboratories Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Falma Laboratories Private Limited
MSME Payment Delays by Falma Laboratories Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Falma Laboratories Private Limited
Subsidiaries & Group Companies of Falma Laboratories Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Falma Laboratories Private Limited with ownership details.
MCA Filings & Documents of Falma Laboratories Private Limited
MCA Filings & Documents of Falma Laboratories Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Falma Laboratories Private Limited
Frequently Asked Questions about Falma Laboratories Private Limited
Falma Laboratories Private Limited is an active private limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 05 December 1985 (41+ years old) and is registered under CIN U24230KA1985PTC007328.
Falma Laboratories Private Limited reported revenue of ₹21,651 for FY 2022 (down 17.15% YoY).
The current directors of Falma Laboratories Private Limited are:
The primary industry of Falma Laboratories Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Falma Laboratories Private Limited can be reached at the registered office: No. 37A2 Pillagumpe Industrial Area Hoskote, Bangalore, Karnataka, India – 562114, or through the website falmalab.com.
The authorised capital is ₹3 Cr, and the paid-up capital is ₹30 Lakh.